Drug Interaction Report

MONITOR: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of capmatinib. According to the prescribing information, capmatinib is primarily metabolized by CYP450 3A4 and aldehyde oxidase. When administered with rifampin, a potent CYP450 3A4 inducer, capmatinib peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by 56% and 67%, respectively. Coadministration with efavirenz, a moderate CYP450 3A4 inducer, decreased capmatinib Cmax and AUC by 34% and 44%, respectively. Data are not available for other, less potent inducers.

MANAGEMENT: The potential for diminished pharmacologic effects of capmatinib should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.

ADJUST DOSING INTERVAL: Coadministration with a high-fat meal may increase the plasma concentrations of olutasidenib. According to the product labeling, administration of a single 150 mg dose with a high-fat meal (approximately 800 to 1000 calories, with approximately 50% of those calories from fat) increased olutasidenib peak plasma concentration (Cmax) and systemic exposure (AUC) by 191% and 83%, respectively, in healthy subjects.

MANAGEMENT: Olutasidenib should be administered at about the same time each day, on an empty stomach at least 1 hour before or 2 hours after a meal.